First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction
- 1 July 2007
- journal article
- clinical trial
- Published by Elsevier BV in American Journal of Obstetrics and Gynecology
- Vol. 197 (1), 35.e1-35.e7
- https://doi.org/10.1016/j.ajog.2007.02.025
Abstract
The purpose of this study was to evaluate first-trimester serum placental protein 13 (PP13) as a screening test for preeclampsia and intrauterine growth restriction (IUGR). We performed a prospective, nested case-control study in the Massachusetts General Hospital Obstetric Maternal Study. PP13 was measured by solid-phase sandwich enzyme-linked immunosorbent assay in serum samples that were collected at the first prenatal visit (9-12 weeks of gestation) from women who subsequently experienced preeclampsia (n = 47), IUGR (n = 42), or preterm delivery (n = 46). Women with uncomplicated term deliveries served as control subjects (n = 290) and were matched to cases by gestational age when serum was collected and for the duration of specimen storage. The median first-trimester PP13 level was 132.5 pg/mL in the control subjects. Median PP13 levels were significantly lower among women who had preeclampsia (27.2 pg/mL; P < .001), IUGR (86.6 pg/mL; P < .001), and preterm delivery (84.9 pg/mL; P = .007). When PP13 was expressed as multiples of the gestational age-specific medians among the control subjects, the multiples of the medians were 0.2 for preeclampsia, 0.6 for IUGR, and 0.6 for preterm delivery (P < .001 for each disorder compared with control subjects). Receiver operating characteristic analysis yielded areas under the curve of 0.91, 0.65, and 0.60 for preeclampsia, IUGR, and preterm delivery, respectively. At a 90% specificity rate, the corresponding sensitivities were 79%, 33%, and 28%, respectively. The screening of maternal PP13 levels in the first trimester is a promising diagnostic tool for the prediction of preeclampsia with high sensitivity and specificity.Keywords
This publication has 37 references indexed in Scilit:
- Vitamins C and E and the Risks of Preeclampsia and Perinatal ComplicationsNew England Journal of Medicine, 2006
- First trimester uterine artery Doppler abnormalities predict subsequent intrauterine growth restrictionAmerican Journal of Obstetrics and Gynecology, 2005
- First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population-based screening study (The FASTER Trial)American Journal of Obstetrics and Gynecology, 2004
- Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnanciesPlacenta, 2004
- Circulating Angiogenic Factors and the Risk of PreeclampsiaNew England Journal of Medicine, 2004
- Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort studyBMJ, 2003
- Preeclampsia: is there value in assessing before clinically evident disease?Published by Ovid Technologies (Wolters Kluwer Health) ,2001
- The Classification and Diagnosis of the Hypertensive Disorders of Pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP)Hypertension in Pregnancy, 2001
- Second-trimester levels of maternal serum human chorionic gonadotropin and inhibin a as predictors of preeclampsia in the third trimester of pregnancyJournal of the Society for Gynecologic Investigation, 2000
- A united states national reference for fetal growthObstetrics & Gynecology, 1996